$695 | Single User
$1395 | Global License

Physician Views: As MannKind's Afrezza nears approval, what opportunity for an inhaled insulin?
[Lowest Price Guaranteed: $695]

Published by FirstWord Pharma: 10 Apr 2014 | 114 | In Stock
Related Topics: FDA , Pfizer

Introduction

Scope



MannKind's confirmation that the FDA has extended the PDUFA date for its inhaled insulin Afrezza to July suggests that the diabetes treatment has a better chance of gaining approval. The most likely alternative scenario, postulated analysts, was receipt of a third complete response letter (CRL) from the FDA.


Despite some residual concerns from FDA staff – primarily focusing on the long-term effects of using an inhaled insulin product and a debatable hypoglycaemic benefit for Afrezza – MannKind received an overwhelmingly positive vote from members of an advisory committee last week.


Assuming the standard three month PDUFA delay has been driven mainly by logistical factors – the AdCom occurred just 10 days ahead of its original PDUFA date – and approval is secured later this summer, attentions will rapidly turn to the commercial opportunity for Afrezza – see ViewPoints: Focus switches to commercial outlook for MannKind's inhaled insulin Afrezza.


On the face of it, an effective inhaled insulin product would be a welcome addition to the diabetes armatorium, a view shared by last week's AdCom panel. However, Pfizer's Exubera – which was launched in the US in September 2006, but withdrawn due to lack of commercial success just 13 months later – casts a shadow over the market.


Despite what the AdCom considered to the modest efficacy of Afrezza versus subcutaneous short-acting insulins, it suggested approval should be granted for both type 1 and 2 diabetes patients on the basis of its inhaled delivery providing a useful benefit in certain patient sub-groups. Discussion also focused on the need for post-marketing studies and lack of sufficient data relating to potential pulmonary and cancer risks.


Puchase Reasons


To ascertain how Afrezza may perform if it is approved by the FDA in July, FirstWord polled US-based endocrinologists this week in order to gauge their opinion towards the drug. Specifically, we asked them...


  • How familiar they are with the development of Afrezza?

  • Based on available Phase III data, to what percentage of type 1 diabetes patients they would anticipate prescribing Afrezza to 12 months after launch?

  • Based on available Phase III data, to what percentage of type 2 diabetes patients they would anticipate prescribing Afrezza to 12 months after launch?

  • To what patient sub-group the availability of an inhaled insulin product would provide the most benefit?

  • What will act as their primary reason for non-use of Afrezza, assuming FDA approval is granted

  • Table of Contents
    for Physician Views: As MannKind's Afrezza nears approval, what opportunity for an inhaled insulin?

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    114 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: As MannKind's Afrezza nears approval, what opportunity for an inhaled insulin? | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...